The indication for these drugs is hereditary transthyretin-mediated amyloidosis, in which the TTR protein destabilized by mutations is deposited extracellularly as fibrillar insoluble amyloids, causing organ dysfunction [92]. This evidence concerns the gene TTR and amyloidosis.